Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Data Showed Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function
Amgen - Investors - RSS Content
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.